VFDB - antivirulence drug 5beta,6alpha-Bis[4-(4-methoxyphenyl)-1H-1,2,3-triazole-1-ylmethyl]-4,5,6,7-tetrahydro-1H-benzoimidazole-2-amine

Acinetobacter

Aeromonas

Anaplasma

Bacillus

Bartonella

Bordetella

Brucella

Burkholderia

Campylobacter

Chlamydia

Clostridium

Corynebacterium

Coxiella

Enterococcus

Escherichia

Francisella

Haemophilus

Helicobacter

Klebsiella

Legionella

Listeria

Mycobacterium

Mycoplasma

Neisseria

Pseudomonas

Rickettsia

Salmonella

Shigella

Staphylococcus

Streptococcus

Vibrio

Yersinia

5beta,6alpha-Bis[4-(4-methoxyphenyl)-1H-1,2,3-triazole-1-ylmethyl]-4,5,6,7-tetrahydro-1H-benzoimidazole-2-amine

Drug details:
Molecular formula: C₂₇H₂₉N₉O₂

Standard name: (5R,6R)-5,6-bis[[4-(4-methoxyphenyl)triazol-1-yl]methyl]-4,5,6,7-tetrahydro-1H-benzimidazol-2-amine

Classification: Anisoles; Phenol ethers; Benzenoids; Organic compounds;

Curated SMILES: C1(N)=NC2CC(CN3N=NC(C4C=CC(OC)=CC=4)=C3)C(CN3N=NC(C4C=CC(OC)=CC=4)=C3)CC=2N1

Chemical structure:

Pseudomonas
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation.
Max phase: In vitro
Publication:
Huigens RW 3rd, et al., 2009. Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 7(4):794-802.


	Back to Top

2004-2024 NIPB, CAMS&PUMC